ESC 24: POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI
ranscatheter aortic valve implantation (TAVI) is a rapidly growing treatment option for patients with aortic valve stenosis. Stroke is a feared complication of TAVI, with an incidence of around 4-5% in the first 30 days. Up to 50% of patients undergoing TAVI have an indication for oral anticoagulants (OAC) mostly for atrial fibrillation. OAC use during TAVI could increase bleeding complications, but interruption during TAVI may increase the risk for thromboembolic events (i.e. stroke, systemic embolism, myocardial infarction). Recent observational data suggest that periprocedural continuation of OAC is safe and might decrease the risk of stroke. Beside the potential reduction of thromboembolic events, continuation of OAC is associated with an evident clinical ancillary benefit for patients and staff. Since periprocedural OAC interruption not infrequently leads to misunderstanding and potentially dangerous situations, when patients are not properly informed before hospital admission or may experience difficulties with the interruption regimen.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
Visit Radcliffe Vascular: https://www.radcliffevascular.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: https://x.com/radcliffeCARDIO
Watch video ESC 24: POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI online without registration, duration hours minute second in high quality. This video was added by user Radcliffe Cardiology 04 September 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 26 once and liked it people.